Selected research
Market Structure
Global Anti-Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-Migraine Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-Migraine Drugs include Allergan, Endo, Impax Laboratories, AstraZeneca, Amgen, Bayer, GlaxoSmithKline, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-Migraine Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-Migraine Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Migraine Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Migraine Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Migraine Drugs Segment by Company
Allergan
Endo
Impax Laboratories
AstraZeneca
Amgen
Bayer
GlaxoSmithKline
Pfizer
Eli Lilly
Merck
Johnson & Johnson
Teva
Eisai
Abbott
Anti-Migraine Drugs Segment by Type
Ergots
Triptans
Others
Anti-Migraine Drugs Segment by Application
Women
Men
Anti-Migraine Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-Migraine Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Ergots
- Triptans
- Others
Applications
- Women
- Men
Companies covered
- Allergan
- Endo
- Impax Laboratories
- AstraZeneca
- Amgen
- Bayer
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Merck
- Johnson & Johnson
- Teva
- Eisai
- Abbott
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-Migraine Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-Migraine Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-Migraine Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-Migraine Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-Migraine Drugs Market Dynamics
- 2.1 Anti-Migraine Drugs Industry Trends
- 2.2 Anti-Migraine Drugs Industry Drivers
- 2.3 Anti-Migraine Drugs Industry Opportunities and Challenges
- 2.4 Anti-Migraine Drugs Industry Restraints
3 Anti-Migraine Drugs Market by Manufacturers
- 3.1 Global Anti-Migraine Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-Migraine Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-Migraine Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-Migraine Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Migraine Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-Migraine Drugs Manufacturers, Product Type & Application
- 3.7 Global Anti-Migraine Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Migraine Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Migraine Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Migraine Drugs Market by Type
- 4.1 Anti-Migraine Drugs Type Introduction
- 4.1.1 Ergots
- 4.1.2 Triptans
- 4.1.3 Others
- 4.2 Global Anti-Migraine Drugs Sales by Type
- 4.2.1 Global Anti-Migraine Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-Migraine Drugs Sales by Type (2021-2032)
- 4.2.3 Global Anti-Migraine Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-Migraine Drugs Revenue by Type
- 4.3.1 Global Anti-Migraine Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-Migraine Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Anti-Migraine Drugs Revenue Market Share by Type (2021-2032)
5 Anti-Migraine Drugs Market by Application
- 5.1 Anti-Migraine Drugs Application Introduction
- 5.1.1 Women
- 5.1.2 Men
- 5.2 Global Anti-Migraine Drugs Sales by Application
- 5.2.1 Global Anti-Migraine Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-Migraine Drugs Sales by Application (2021-2032)
- 5.2.3 Global Anti-Migraine Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-Migraine Drugs Revenue by Application
- 5.3.1 Global Anti-Migraine Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-Migraine Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Anti-Migraine Drugs Revenue Market Share by Application (2021-2032)
6 Global Anti-Migraine Drugs Sales by Region
- 6.1 Global Anti-Migraine Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-Migraine Drugs Sales by Region (2021-2032)
- 6.2.1 Global Anti-Migraine Drugs Sales by Region (2021-2026)
- 6.2.2 Global Anti-Migraine Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-Migraine Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-Migraine Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-Migraine Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-Migraine Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-Migraine Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-Migraine Drugs Revenue by Region
- 7.1 Global Anti-Migraine Drugs Revenue by Region
- 7.1.1 Global Anti-Migraine Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-Migraine Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Anti-Migraine Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Anti-Migraine Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-Migraine Drugs Revenue (2021-2032)
- 7.2.2 North America Anti-Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-Migraine Drugs Revenue (2021-2032)
- 7.3.2 Europe Anti-Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-Migraine Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-Migraine Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-Migraine Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Allergan
- 8.1.1 Allergan Company Information
- 8.1.2 Allergan Business Overview
- 8.1.3 Allergan Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Allergan Anti-Migraine Drugs Product Portfolio
- 8.1.5 Allergan Recent Developments
- 8.2 Endo
- 8.2.1 Endo Company Information
- 8.2.2 Endo Business Overview
- 8.2.3 Endo Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Endo Anti-Migraine Drugs Product Portfolio
- 8.2.5 Endo Recent Developments
- 8.3 Impax Laboratories
- 8.3.1 Impax Laboratories Company Information
- 8.3.2 Impax Laboratories Business Overview
- 8.3.3 Impax Laboratories Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Impax Laboratories Anti-Migraine Drugs Product Portfolio
- 8.3.5 Impax Laboratories Recent Developments
- 8.4 AstraZeneca
- 8.4.1 AstraZeneca Company Information
- 8.4.2 AstraZeneca Business Overview
- 8.4.3 AstraZeneca Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 AstraZeneca Anti-Migraine Drugs Product Portfolio
- 8.4.5 AstraZeneca Recent Developments
- 8.5 Amgen
- 8.5.1 Amgen Company Information
- 8.5.2 Amgen Business Overview
- 8.5.3 Amgen Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Amgen Anti-Migraine Drugs Product Portfolio
- 8.5.5 Amgen Recent Developments
- 8.6 Bayer
- 8.6.1 Bayer Company Information
- 8.6.2 Bayer Business Overview
- 8.6.3 Bayer Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bayer Anti-Migraine Drugs Product Portfolio
- 8.6.5 Bayer Recent Developments
- 8.7 GlaxoSmithKline
- 8.7.1 GlaxoSmithKline Company Information
- 8.7.2 GlaxoSmithKline Business Overview
- 8.7.3 GlaxoSmithKline Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GlaxoSmithKline Anti-Migraine Drugs Product Portfolio
- 8.7.5 GlaxoSmithKline Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Company Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pfizer Anti-Migraine Drugs Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Eli Lilly
- 8.9.1 Eli Lilly Company Information
- 8.9.2 Eli Lilly Business Overview
- 8.9.3 Eli Lilly Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Eli Lilly Anti-Migraine Drugs Product Portfolio
- 8.9.5 Eli Lilly Recent Developments
- 8.10 Merck
- 8.10.1 Merck Company Information
- 8.10.2 Merck Business Overview
- 8.10.3 Merck Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Merck Anti-Migraine Drugs Product Portfolio
- 8.10.5 Merck Recent Developments
- 8.11 Johnson & Johnson
- 8.11.1 Johnson & Johnson Company Information
- 8.11.2 Johnson & Johnson Business Overview
- 8.11.3 Johnson & Johnson Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Johnson & Johnson Anti-Migraine Drugs Product Portfolio
- 8.11.5 Johnson & Johnson Recent Developments
- 8.12 Teva
- 8.12.1 Teva Company Information
- 8.12.2 Teva Business Overview
- 8.12.3 Teva Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Teva Anti-Migraine Drugs Product Portfolio
- 8.12.5 Teva Recent Developments
- 8.13 Eisai
- 8.13.1 Eisai Company Information
- 8.13.2 Eisai Business Overview
- 8.13.3 Eisai Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Eisai Anti-Migraine Drugs Product Portfolio
- 8.13.5 Eisai Recent Developments
- 8.14 Abbott
- 8.14.1 Abbott Company Information
- 8.14.2 Abbott Business Overview
- 8.14.3 Abbott Anti-Migraine Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Abbott Anti-Migraine Drugs Product Portfolio
- 8.14.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-Migraine Drugs Value Chain Analysis
- 9.1.1 Anti-Migraine Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-Migraine Drugs Production Mode & Process
- 9.2 Anti-Migraine Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-Migraine Drugs Distributors
- 9.2.3 Anti-Migraine Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst